🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Delayed nephrectomy after ICIs for metastatic RCC: •65.7% faced surgical complexity •Median blood loss: 300 mL •Median tumor downsizing: 19.7% •48% of patients remained progression-free & off systemic tx #kidneycancer link.springer.com/article/10.100…

#kidneycancer Patients want to be cured. They will accept treatments that increase survival - but they want cure. Thanks David Braun for continuing to repeat this mantra and for your efforts to make it a reality. shorturl.at/OIVjE

Dena Battle presenting at Pfizer Inc. advocacy breakfast at #GU25 on disease burden. Such important reminder to balance between treatments and making sure patients are not consumed by them. #RCC

#GU35 44% of #kidneycancer pts spend HOURS thinking about cancer. In last 90 days, 36% have gone to ER. >1/3 of patients say that cancer always/often impacts their ability to eat, sleep and engage with family and friends. Surviving is not the same as living. #diseaseburdenzero

Burden of mRCC – Insights from KCCure survey 🛑 36% visited the ER, 23% hospitalized, 44% spend hours daily thinking about cancer 💊 1 in 3 worried about taking too many meds 🧬 More research needed to improve care & QoL! KCCure Dena Battle ASCO Yüksel Ürün #GU25

Great Poster by our friends at KCCure at #GU25 Spoke to First Author Dena Blattle Dena Battle who tells us more: Disease Burden in mRCC #kidneycancer pts spend HOURS⏳ thinking about #cancer. In last 9⃣0⃣ days, 36% have gone to ER. >1/3 of patients say that cancer

Tian Zhang, MD, MHS with masterful discussion of kry presentations from Laurence Albiges Robert Motzer MD Katy Beckermann #GU24

Clear cell RCC is heterogeneous. UTSW Simmons Cancer Center’s Tian Zhang, MD, MHS presents the new frontier and dares us to imagine patients unique disease treated uniquely. #GU25 #kidneycancer #diseaseburdenzero

18F-PSMA-1007 PET/CT for response assessment in patients with #mRCC undergoing first-line tyrosine kinase or checkpoint inhibitor therapy. Presentation by Michael Staehler. #GU25 written coverage by Zach Klaassen > bit.ly/3QrawzP

70% of health-related internet searches are zero-click - which means pts are relying on snippets and AI overviews for information. When you see something like this that is outdated, misleading, or both - click on the feedback button. It's a small way you can help improve

Global Effect of Cardiovascular Risk Factors on Lifetime Estimates: NEJM 🥸 Great work from Germany on global life time risk of CVD risk 😱 Summary 👇👇👇

One day left for early registration to attend the 2025 IKCS: Europe! #IKCSEU25 See you in Amsterdam, May 1-3 for an exciting #kidneycancer meeting and the opportunity to network with others passionate about making a difference for patients! Register: kidneycancer.org/event/2025-ikc…

🎉CONGRATULATIONS to Michael Staehler, recipient of the KCA's 2025 John Fitzpatrick Award recognizing excellence in urology care! The award will be presented at #IKCSEU25, don't miss his lecture! kidneycancer.swoogo.com/IKCSEU25

Good morning everyone, #IKCSEU25 begins TODAY 🎊 🎉 We are excited to come together here in Amsterdam talk about the future of #kidneycancer and how best to care for the patients who are counting on us. Looking forward to the next few days!

Congratulations Michael Staehler, recipient of #FitzgeraldAward Kidney Cancer #IKCSEU25! Legacy and innovation. Sets challenges and vision for our field to find the right patients for the right treatments.

Great job Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ! Do not miss all the research articles from Linnea Olsson, Michael Staehler Laura Bukavina David Jin, Lars Lund. Thank you all for your contributions!!

Join Dr. Sumanta Kumar Pal (Sumanta K. Pal, MD, FASCO) & colleagues on Saturday, May 31, at 6:30 PM CDT/7:30 PM EDT during #ASCO25 for a #RenalCellCarcinoma #MedEd event. Produced with @KCCure. bit.ly/4mdScJu #KidneyCancer #Oncology

Glimpses of #IKCSEU25!

Just a week away! Please join us in Chicago at this Peerview event, 7pm central on Sat 5/31! Register here: lrn.peerview.com/150210496_1/15…

📣 Live at #ASCO25: Learn from real-world #RCC cases with Sumanta K. Pal, MD, FASCO, Dr. McDermott & Tian Zhang, MD, MHS  ✅ IO-based regimens  ✅ Sequencing therapies  ✅ Shared decision-making  🗓️ May 31 | 7:00 PM CDT  🔗 bit.ly/RCC-T